Lucia Tornaghi
University of Milano-Bicocca
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Lucia Tornaghi.
The Lancet | 2003
Carlo Gambacorti-Passerini; Lucia Tornaghi; Francesco Cavagnini; Pellegrino Rossi; Francesca Pecori-Giraldi; Luigi Mariani; Nadia Cambiaghi; E Pogliani; Gianmarco Corneo; Lucio Gnessi
cKit and platelet-derived growth-factor receptor (PDGFR) are receptor tyrosine kinases expressed in the testis, are involved in testosterone production, and are inhibited by imatinib. We measured hormone concentrations in 38 men receiving imatinib for chronic myeloid leukaemia at baseline and during treatment. Mean follow-up was 23.6 months (SD 7.5). We noted seven cases of gynaecomastia (18%, 95% CI 6-30%). A comparison of hormone concentrations in 21 patients before and during treatment showed that patients who developed gynaecomastia had a reduction in free testosterone concentrations of 29.53 pmol/L (95% CI 11.63-47.43), while patients who did not had a decrease of 6.36 pmol/L (-1.02 to 13.74). In most men with chronic myeloid leukaemia studied here, imatinib was associated with a reduction in the production of testicular hormones and in some, with the development of gynaecomastia.
Haematologica | 2008
A Franceschino; Lucia Tornaghi; Benemacher; Sarit Assouline; Carlo Gambacorti-Passerini
Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.
Transfusion | 2005
Paolo Perseghin; Carlo Gambacorti-Passerini; Lucia Tornaghi; Maria Dassi; Pietro Pioltelli; Matteo Parma; Federica Colnaghi; Giovanni Giudici; Elena Elli; Monica Fumagalli; Luisa Ponchio; Andrea Biondi; Enrico Maria Pogliani
BACKGROUND: Imatinib mesylate (IM) was introduced in chronic myeloid leukemia (CML) treatment in the late 1990s and substantially changed the therapeutic approach to the disease, by inducing complete cytogenetic response (CCR) in approximately 60 percent of cases. Nevertheless, some concerns exist about the duration of response to treatment and the onset of resistance to IM.
Leukemia | 2005
Rocco Piazza; Vera Magistroni; F Andreoni; A Franceschino; Lucia Tornaghi; M Varella-Garcia; S Bungaro; Federica Colnaghi; Gianmarco Corneo; E Pogliani; Carlo Gambacorti-Passerini
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients
Nature Medicine | 2007
Carlo Gambacorti; Lucia Tornaghi; A Franceschino; Rocco Piazza; Gianmarco Corneo; E Pogliani
Blood Cells Molecules and Diseases | 2002
Carlo Gambacorti-Passerini; Francesca Rossi; Magda Verga; Holger Ruchatz; Rosalind H. Gunby; Roberta Frapolli; Massimo Zucchetti; Leonardo Scapozza; Silvia Bungaro; Lucia Tornaghi; Fabio Rossi; Pietro Pioltelli; E Pogliani; Maurizio D'Incalci; Gianmarco Corneo
Blood | 2007
Carlo Gambacorti-Passerini; Lucia Tornaghi; Elena Marangon; A Franceschino; Enrico Maria Pogliani; Maurizio D'Incalci; Massimo Zucchetti
Leukemia Research | 2010
Stefania Mariani; Lucia Tornaghi; Marianna Sassone; Sabrina Basciani; Raffaella Buzzetti; Carlo Gambacorti-Passerini; Giovanni Spera; Lucio Gnessi
Blood Cells Molecules and Diseases | 2006
Rocco Piazza; Vera Magistroni; A Franceschino; F Andreoni; Lucia Tornaghi; Federica Colnaghi; Gianmarco Corneo; E Pogliani; Carlo Gambacorti-Passerini
Haematologica | 2006
A Franceschino; Lucia Tornaghi; Rocco Piazza; E Pogliani; C Gambacorti Passerini
